Tools
Central Pain Syndrome
Introduction
Central sensitization occurs when the nervous system remains in a state of hyperactivity, resulting in increased neuronal excitability and enhanced synaptic transmission.[1][2] Despite limited input from the peripheral nervous system (PNS), the central nervous system (CNS) persistently amplifies pain signals. This hyperexcitability results in heightened pain sensitivity through the upregulation of ion channels, reduced inhibition, and maladaptive plasticity.[3] This state, which includes "wind-up" (temporal summation) as an acute precursor, causes ordinary touch to produce pain (allodynia) or a mild stimulus to feel more painful (hyperalgesia).[4]
Central pain syndrome (CPS), a subset of centralized pain disorders, results from CNS conditions such as stroke or spinal cord injury. CPS involves mechanisms distinct from those of nociplastic pain, such as that seen in fibromyalgia. While less common than nociplastic pain, CPS often develops following neurological injuries, making it crucial for healthcare providers to differentiate it from other centralized pain syndromes to guide appropriate interventions. Cold temperatures or emotional stress may exacerbate symptoms but are not required for diagnosis.
CPS frequently coexists with memory impairment and anxiety, reflecting shared neurobiological pathways. Treatment involves targeted CNS therapies, including antidepressants like serotonin-norepinephrine reuptake inhibitors (SNRIs) and anticonvulsants such as gabapentin. Traditional pain relievers, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, are typically ineffective for centrally mediated pain. Chronic pain affects up to 1 in 5 adults, with a substantial proportion experiencing centralized pain symptoms.[5]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Historically, CPS was considered a psychiatric diagnosis following traumatic brain injury or thought to be a diagnosis of exclusion. The theory behind CPS was that it represented a dysfunction of the nervous system, unlike adaptive changes seen with musculoskeletal (nociceptive) pain.[6] For example, withdrawing one's hand from an open flame is beneficial, as pain serves as a protective mechanism to limit harm. CPS, however, was thought to represent pain without protective value. Not only is it nonprotective, but it is also maladaptive.
Sensory amplification and pain intensify as multiple systemic syndromes overlap. An estimated 2% to 4% of the population experience fibromyalgia, 1% have chronic fatigue, and 4% live with somatoform disorders. Additionally, regional pain syndromes and psychiatric disorders have a significant overlap.
CPS is a type of neuropathic pain that originates in the CNS. The condition can occur in patients with a history of multiple sclerosis or recent stroke. Acute pain that becomes chronic may undergo centralization, putting patients at risk of developing centralized pain.
Although patients with CPS consider their pain to be peripheral, it is mostly centralized. The neural signal becomes amplified, leading to hyperalgesia and allodynia. Pain centralizes over time when peripheral pain occurs with nociceptive pain, such as in rheumatoid arthritis. The pain then enters a mixed state. Chronic back pain serves as an example of peripheral pain centralizing with time.[7][8]
Risk factors for fibromyalgia mirror those for CPS. These risk factors include trauma, infection, chronic stress, obesity, and depression. Centralized sensitization occurs with minimal or no nociceptive input. Functional neuroimaging can aid in the diagnosis of CPS.
In reality, centralized pain is not mutually exclusive from other types of pain. An overlap exists between pain states. Any central pain state can include a component of peripheral pain, such as peripheral neuropathy. Additionally, a significant family predisposition to CPS exists.[9][10] Psychological stressors can also trigger worsening symptoms. In many cases, environmental factors cause a triggering event in patients with genetic susceptibility, leading to widespread, centralized pain.[11][12] Thus, environmental stressors require management. Early life trauma, infection, or emotional stress can cause centralized pain in 5% to 10% of patients.[13][14]
An estimated 50% environmental component contributes to developing centralized pain, with a 50% genetic component. First-degree relatives face an 8-fold higher risk of developing centralized pain compared to the general population. However, no significant difference exists based on the sex of the patient or family member. The genetic association is more prominent in families with a history of mood disorders.[15][16] A genetic component for centralized pain may exist, but a single genetic polymorphism has not been identified.[17]
Epidemiology
Chronic widespread pain seen in centralized pain occurs in 10% to 40% of patients with rheumatoid arthritis, psoriatic arthritis, osteoarthritis, spondyloarthritis, and systemic lupus erythematosus (SLE). Centralized pain occurs in 5% to 15% of the general population, most of whom have fibromyalgia. The criteria for fibromyalgia diagnosis overlap considerably with centralized pain, with patients who report severe fatigue having a fivefold increased risk for widespread pain.[18] The prevalence of overlap between centralized pain and knee osteoarthritis ranges from 10% to 15%. The prevalence increases if knee pain is bilateral compared to unilateral knee pain.[19][20][21]
The reported centralized pain in rheumatoid arthritis is estimated to be 13% to 40%. One concern with this patient population is overtreating rheumatoid arthritis due to increased symptoms, which actually arise from centralized pain. Inflammatory markers are lower in patients with comorbid fibromyalgia and rheumatoid arthritis, while these patients report a decreased quality of life compared to those with rheumatoid arthritis alone.[22][23]
Centralized pain appears in 10% to 30% of patients with spondyloarthritis. Separately, 13% to 20% of patients with ankylosing spondylitis meet the criteria for fibromyalgia.[24][25][26] Patients with widespread pain are much more likely to have clinically significant fatigue with a comorbid mood disorder, with moderate-to-severe symptoms. In one study, centralized pain was present in 53% of patients with psoriatic arthritis but only 5% of the average population.[27] Patients with centralized pain were also more likely to be lost to follow-up after initiating treatment. Separately, centralized pain presents in 20% to 40% of patients with SLE or Sjögren syndrome. Furthermore, symptoms were more prevalent as chronic diseases progressed and in patients with comorbid depression.[28][29]
Over 1/3 of women with chronic back pain suffer from centralized pain. The daily impact of centralized pain is significant in patients with chronic back pain, including severe limitations in their activity level. Given the considerable prevalence of widespread, centralized pain in women with chronic low back pain, CPS warrants consideration in the differential diagnosis for this patient population.[30]
Pathophysiology
The pathogenesis of CPS remains unclear. The underlying mechanism may resemble that of neuropathic pain arising from other body regions or may involve overlapping lesions, features, and associated conditions.[31] Both central and peripheral mechanisms contribute to neuropathic pain, including alterations in the brain, spinal cord, and descending modulatory pathways.[32] Commonly affected regions include the lateral medulla, pontine base, and lateral or posterior thalamus.[33]
Toxicokinetics
No current peer-reviewed data demonstrate a link between any specific toxin and CPS. However, any etiology capable of inducing chronic pain, such as chemical, drug (eg, disease-modifying antirheumatic drugs), or venom exposure, may plausibly contribute to centralized pain through chronic pain mechanisms.[34]
History and Physical
The diagnosis of CPS requires symptoms persisting for a minimum of 3 months, characterized by widespread allodynia or hyperalgesia in the absence of an identifiable nociceptive source. CPS is defined by the International Association for the Study of Pain (IASP) as pain caused by a CNS lesion or disease. Central sensitization, characterized by increased responsiveness of nociceptive neurons in the CNS to normal or subthreshold input, is a key mechanism that may contribute to the condition. CPS may present as generalized pain or involve multiple, discrete anatomical regions. Reproducible pain elicited by normal pressure during palpation typically reflects hyperalgesia or allodynia secondary to mechanical stimulation of joints or muscles.
Clinical features frequently associated with CPS include mood disturbances, fatigue, cognitive impairment, disordered sleep, pain catastrophizing, and symptoms suggestive of neuropathic pain, such as burning, numbness, tingling, and paresthesias. Affected individuals often report multifocal pain and memory complaints, and may meet diagnostic criteria for major depressive or generalized anxiety disorder. Noxious stimuli, such as extreme temperatures or loud auditory input, may exacerbate symptom intensity.[35] Using a standardized body diagram may assist in documenting pain distribution.
A thorough pain history should include the onset, description, location, radiation, quality, and severity of the pain. Additional elements include the mechanism of injury (if applicable), aggravating and relieving factors, frequency of symptoms, and presence of breakthrough pain. Associated features should also be assessed, such as muscle spasms or aches, temperature changes, restricted range of motion, morning stiffness, weakness, muscle strength, sensory changes, and alterations in hair, skin, or nail integrity.
Separately, the physical examination should include a detailed neurological assessment and a focused examination of the painful area. When evaluating for CPS, a complete musculoskeletal examination is recommended. Assessment for symmetrical tender points, characteristic of fibromyalgia, may also provide diagnostic insight. Ay tenderness over soft tissues or joints should be documented.
To support a diagnosis of CPS, pain often appears in a widespread distribution, affecting the axial skeleton, both sides of the body, and regions above and below the diaphragm. CPS becomes less likely when findings include swelling, structural abnormalities, focal neurologic deficits, or signs of joint inflammation.
Evaluation
The diagnosis of CPS remains primarily clinical, as the results of standard laboratory tests, including complete blood count, erythrocyte sedimentation rate, C-reactive protein, thyroid-stimulating hormone, and creatine kinase, are typically unremarkable.[36] Laboratory testing should be reserved for cases with clinical suspicion warranting further evaluation. Genetic biomarkers for CPS are currently limited, and rheumatologic markers such as rheumatoid factor and antinuclear antibody are not indicated unless an autoimmune process is suspected.
Screening tools for CPS include the Central Sensitization Inventory (CSI) and painDETECT. These modalities assist in evaluating neuropathic pain and centralized pain syndromes such as fibromyalgia, respectively.[37] Distinguishing between central and peripheral origins of pain can be challenging. For instance, painDETECT cannot localize the source of pain to either the CNS or PNS with precision.[38]
Neuroimaging, including magnetic resonance imaging (MRI) and functional MRI (fMRI), may support the diagnosis of CPS. FMRI has identified structural and functional brain alterations in patients with chronic pain conditions. Individuals with fibromyalgia, for example, often demonstrate distinct brain activation patterns. FMRI may help identify patients at risk for developing centralized pain disorders and contribute to diagnosis and prognosis.[39] Notable fMRI findings include reduced brain volume, decreased cortical thickness, and elevated levels of excitatory neurotransmitters.[40]
Furthermore, fMRI provides insight into connectivity between multiple brain regions, with the degree of alteration often correlating with the extent of a patient's pain. In fibromyalgia, fMRI may offer an objective measure of symptom severity.[41] Patients with fibromyalgia demonstrate pain-related brain activity patterns that differ from those in the general population. As a diagnostic tool, fMRI shows promise for future use in evaluating various chronic pain disorders.[42] Positron emission tomography (PET) and electroencephalography (EEG) have also revealed heightened pain responses in individuals with CPS.[43][44]
Treatment / Management
Treatment often targets the underlying chronic disease associated with centralized pain. Managing comorbid conditions can significantly reduce pain severity.[45] For instance, in knee osteoarthritis, neuroimaging abnormalities linked to centralized pain have improved following joint replacement. Central pain disorders tend to respond more effectively to neuromodulators, antiepileptics, or antidepressants than to pharmacologic agents targeting peripheral pain, such as NSAIDs or opioids.(B2)
Nonpharmacological strategies, particularly cognitive-behavioral therapy, serve as a foundation for managing CPS. A comprehensive, individualized approach is essential, as the underlying pathology may involve structural, immunologic, or inflammatory mechanisms. Strong evidence supports the use of neuromodulation techniques in the management of chronic pain. These methods include deep brain and motor cortex stimulation, peripheral nerve stimulation, and noninvasive modalities such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and transcutaneous electrical nerve stimulation (TENS).[46]
Self-directed or therapist-directed physical therapy techniques can include traction, massage, ultrasonographic therapy, hot or cold applications, positioning, meditation, active visualization, prayer, stretching exercises, and transcutaneous electrical nerve stimulation (TENS). Female patients with chronic pelvic pain syndrome may benefit from myofascial physical therapy, which can alleviate hypertonicity, improve endogenous inhibitory system function, reduce sensitivity to experimental pain, and provide psychological benefits.[47]
TENS is commonly used to treat rheumatoid arthritis and osteoarthritis. Electrodes are placed over or near the pain site, with the dipole positioned parallel to major nerve trunks. However, TENS can cause hypersensitivity as a side effect and should be avoided in individuals who are pregnant, have demand-type pacemakers, or intend to use it near the carotid sinus. Motor cortex (MCS) and deep brain (DBS) stimulation are effective treatment options for patients with refractory pain, central pain, and peripheral neuropathy.[48]
Occupational therapy proves beneficial for patients with chronic pain, particularly those with regional chronic pain syndrome. Occupational therapy promotes physical activity and helps manage physical symptoms.
Pharmacological treatments for CPS include tricyclic antidepressants, SNRIs, and anticonvulsants. Strong evidence supports the use of tricyclic antidepressants like amitriptyline, SNRIs like duloxetine and venlafaxine, and anticonvulsants like pregabalin and gabapentin. Moderate evidence exists for tramadol and selective serotonin reuptake inhibitors, while weak evidence supports the use of S-adenosyl-L-methionine.
Differential Diagnosis
Central sensitization manifests in various chronic pain disorders, including fibromyalgia, interstitial cystitis, temporomandibular joint disease, and irritable bowel syndrome. The differential diagnosis for CPS is broad, encompassing autoimmune disorders such as rheumatoid arthritis and polymyalgia rheumatica, myopathies, painful peripheral neuropathies, somatization disorder, malingering, and withdrawal phenomena from physiological or psychological dependence on habit-forming substances.
Central sensitization frequently accompanies chronic back and neck pain and is also associated with conditions such as trauma, carpal tunnel syndrome, complex regional pain syndrome, lateral epicondylitis, osteoarthritis, and joint hypermobility syndrome. CPS develops following a stroke or as a sequela of neurological disorders like multiple sclerosis.[49][50] A thalamic stroke is linked to a specific form of CPS. Finally, mood disorders, including major depressive disorder and generalized anxiety disorder, are often comorbid with CPS.
Toxicity and Adverse Effect Management
Potential Complications of Central Pain Syndrome Management
Adverse events from pain management procedures, when performed by well-trained and experienced interventionalists, are rare. The most common complication is a vasovagal response.[51] However, serious complications can arise, such as spinal block with critical hypotension, central respiratory depression from high cervical block, cardiac rhythm disturbances from inadvertent vascular uptake of injectate, acute contrast agent reactions, and pneumothorax. These complications require prompt management. Follow-up is essential not only for assessing the response and deciding whether to repeat or alter the procedure, but also for monitoring delayed infectious complications such as infectious discitis, epidural abscess, meningitis, and cellulitis.
Opiates, particularly when combined with other sedating medications, can cause respiratory depression. A responsible adult should be trained in the use of nasal naloxone. All sedating medications, including membrane stabilizers, whether alone or in combination, increase the risk of falls and related injuries, such as fractures, subdural hematomas, and even cognitive impairments that can hinder participation in cognitive behavioral therapies. The use of serotonergic drugs, either alone or in combination with tramadol (Controlled Substance Schedule IV), poses a significant drug interaction risk and carries the often-overlooked risk of serotonin syndrome.[52][53] Other medications, such as antineoplastics, also come with specific toxicities.
Most patients with CPS, or any chronic neuropathic pain, typically exhibit some degree of sensory peripheral neuropathy, which increases the risk of falls. This risk should be considered during physical and occupational therapy. Gait belts with contact guard assistance should be used for any patient with even slight balance issues.
Treatment Caveats
Individuals with CPS, like those with other chronic illnesses, often explore alternative or experimental therapies. Some may order "magic pain pills" online or mortgage their homes to travel abroad for treatment with a clinician who promises to "easily cure all these cases." While medical tourism is growing and some patients benefit from international treatment, patients are often vulnerable to exploitation, making such claims warrant careful evaluation. Oral and topical alternatives, such as herbal treatments and methylene blue, are receiving more research attention.[54] However, drug-herb and drug-chemical interactions should be carefully considered.
Another consideration is the lack of regulation. While some herbs or chemicals are well-established for their beneficial effects, product labels may not always accurately reflect the actual contents or confirm the absence of harmful substances, such as heavy metals.
Medical Oncology
Medical oncology consultation is warranted when malignancy is suspected, acute inflammatory markers are elevated without an identifiable cause, treatment of primary or metastatic lesions is indicated, or external beam radiation is being considered. Pain management in cancer survivors and patients undergoing cancer therapies involves special considerations, and a physician capable of recommending cannabis may be indicated.[55] In the U.S., relevant guidelines vary by state.
Prognosis
Prognosis improves in patients when the underlying disease causing pain can be cured, corrected, or managed, such as through shoulder replacement for osteoarthritis. Patients with osteoarthritis and centralized sensitization report pain reduction with pharmacological therapy targeting osteoarthritis, but experience worse pain outcomes following joint replacement surgery.[56]
In patients with osteoarthritis comorbid with CPS, pain severity does not correlate with radiographic severity of osteoarthritis. Additionally, patients with radiological evidence of osteoarthritis in a single joint are at increased risk of developing pain in multiple joints. This comorbid population also exhibits more synovitis and effusion in knee osteoarthritis.
Central sensitization contributes to inflammatory arthritis and affects a significant subset of the patient population. For example, patients with rheumatoid arthritis and comorbid fibromyalgia report worse pain, poorer mental health, and greater reliance on pain medications, including prednisone, despite having lower levels of inflammatory markers.[57][58] Patients with inflammatory arthritis and centralized sensitization experience poorer overall outcomes.[59] These patients also experience hyperalgesia at both articular and nonarticular sites.[60]
Complications
The impact of central sensitization extends across various conditions. In rheumatoid arthritis, central pain is linked with neuropathic symptoms, higher pain scores without changes in inflammatory markers, increased adverse outcomes, and reduced remission rates. Central sensitization also contributes to the increased use of opioids and higher pain severity in patients with osteoarthritis, leading to poorer patient outcomes.
Patients with bilateral knee pain are more likely to experience pain in other joints within a year. In spondyloarthritis, central sensitization is associated with worse outcomes, higher disease scores, and poorer treatment responses. In SLE, centralized pain is associated with greater sleep disturbances, mood changes, and worse overall outcomes. Patients with chronic back pain and central sensitization experience more intense pain and mood disturbances, as well as an increase in adverse outcomes. Joint hypermobility syndrome is linked to greater pain severity and poorer patient outcomes.
In carpal tunnel syndrome, central sensitization is associated with poorer surgical outcomes, while in lateral epicondylitis, it correlates with more severe pain, longer duration of pain, and a higher risk of failed treatments. For chronic whiplash injuries, centralized pain is associated with cognitive disturbances, more severe pain, and worse outcomes. Preoperative increases in fibromyalgia pain scores are associated with the use of more postoperative morphine equivalents and a reduced response to NSAIDs.[61]
Postoperative and Rehabilitation Care
Adequate pain control and early therapy following major surgeries are often believed to improve overall outcomes and reduce the incidence of chronic pain and disability. However, articles addressing this topic typically do so in an indirect and nonspecific manner, often focusing on specific disciplines or procedures, which requires extrapolation to broader contexts.[62][63] Nevertheless, the prevention of "sequelae of immobility," such as flexion contractures, deep vein thrombosis, muscle atrophy, compression neuropathies, and malnutrition, is universally accepted and does not require a peer-reviewed reference.
Consultations
The clinical scenario should guide specialist consultations. Rheumatology should be consulted for cases involving potential autoimmune disorders or elevated acute inflammatory markers. Neurology is necessary when concern arises for cerebrovascular accidents or other intracranial pathologies, such as demyelinating plaques.
Physical medicine and rehabilitation can assist with electrodiagnostic evaluations to differentiate between inflammatory and noninflammatory myopathies or identify the presence of peripheral neuropathy, especially if conditions like acute or chronic inflammatory demyelinating polyneuropathy are considered in the differential diagnosis.
Neurosurgery or orthopedic Surgery should be involved if concerns arise about structurally relevant and potentially correctable spinal or peripheral joint pathologies. Neurosurgery may also be required for temporal lobe stimulation in certain cases. Psychiatry or psychology is important for addressing potential somatization or hypochondriasis, as well as providing emotional support in the management of chronic, intractable pain.
Pain management consultations are essential for exploring both interventional and noninterventional options, including medication management and the consideration of implantable technologies, such as subarachnoid pain pumps. Vascular surgery or interventional radiology should be consulted if a vascular etiology is suspected.
Deterrence and Patient Education
CPS arises from heightened sensitivity within the CNS, lowering the threshold for pain perception. Understanding the pathophysiology, prevalence, and management of this condition is crucial for effective deterrence and treatment, especially in patients with chronic disease.
CPS manifests when the CNS becomes hyperresponsive, resulting in conditions like allodynia, or pain from normally nonpainful stimuli, and hyperalgesia, or exaggerated responses to painful stimuli. Up to 20% of individuals with chronic pain from any source may exhibit features of CPS, underscoring its clinical significance. Risk increases in patients with rheumatologic or musculoskeletal conditions persisting longer than 3 months, and both environmental and genetic factors contribute to its development.
Importantly, CPS can coexist with peripheral pain, further complicating diagnosis and management. Over time, chronic disease itself may amplify central sensitization, making dual pain syndromes more common. FMRI has emerged as a valuable diagnostic tool in distinguishing centralized pain patterns, enhancing clinical precision.
CPS affects numerous chronic disease states, notably worsening outcomes in osteoarthritis and rheumatoid arthritis. Addressing both the primary disease and CPS in tandem can lead to better symptom control. Effective management often requires collaboration between a primary care physician (PCP) and a pain medicine specialist. First-line pharmacologic interventions include antidepressants and anticonvulsants, which help modulate abnormal CNS pain processing.
Recognizing and managing centralized pain early in the course of chronic illness may deter progression to more debilitating states. A comprehensive, dual-focused approach offers the best opportunity for improving quality of life in patients with CPS.
Pearls and Other Issues
Clinicians should remember that pain is a symptom, not an etiology or a diagnosis. Every symptom reflects an underlying process, whether identified or not, treatable or not, or yet to be recognized in the current scientific literature. Approximately 20% of individuals with chronic pain from known causes also experience CPS or widespread pain in other regions. Effective treatment requires addressing both the primary cause of pain, acknowledging the limitations in treating certain conditions, and the distressing symptoms themselves, including pain.
Enhancing Healthcare Team Outcomes
Managing CPS requires a coordinated interprofessional approach involving PCPs, pain medicine specialists, pharmacists, nurses, and subspecialists such as rheumatologists or neurologists. Early recognition of centralized pain is essential, as it requires a distinct treatment strategy from peripheral or mechanical pain. CPS is associated with significant morbidity without appropriate diagnosis and management.
Initial evaluation typically includes laboratory tests such as complete blood count, erythrocyte sedimentation rate, C-reactive protein, creatine phosphokinase, and aldolase to help rule out underlying inflammatory or myopathic conditions. Clinicians should assess for hallmark features of central pain, including allodynia and hyperalgesia, particularly in patients with pain persisting longer than 3 months. Both genetic and environmental factors may contribute to the development and persistence of CPS.
Pharmacologic management often involves consultation with a pharmacist to guide the use of antidepressants, anticonvulsants, and other agents, including over-the-counter supplements or experimental options like methylene blue. Pain medicine specialists may consider neuromodulation for refractory cases. FMRI, when available, may provide supportive diagnostic information and should be discussed with a radiologist. Subspecialist input from rheumatology or neurology is often necessary to address underlying autoimmune or neurologic contributors to pain.
Management of CPS requires collaboration across multiple healthcare disciplines. However, coordination challenges frequently arise, with overlapping treatments, redundant testing, and polypharmacy increasing the risk of harm. To ensure consistency and safety, a single lead clinician, often referred to as the “quarterback,” should oversee the overall care plan and track each clinical decision. This role is commonly filled by neurologists or physicians in physical medicine and rehabilitation who hold additional board certification in pain management. Nonetheless, a PCP can also serve in this capacity if they have the interest and expertise, though many PCPs feel underprepared or lack the time to manage such complex cases comprehensively.
Preventing the progression to centralized sensitization is a critical goal due to the high burden of morbidity associated with this condition. Once established, symptoms of CPS are often persistent and do not fully resolve, and long-term outcomes remain guarded despite comprehensive care.
Nursing staff play a critical role in the care of individuals with centralized pain. These professionals serve as liaisons between healthcare professionals, monitor patient progress, and often spend more time with patients than most other team members. Extended time at the bedside improves the likelihood of detecting subtle physical or emotional changes that might otherwise go unrecognized. Nurses' observations, when consistently communicated with the care team, can significantly influence management decisions. Nurses also provide ongoing education and support, helping patients navigate their treatment plans and maintain realistic expectations.
Physical and occupational therapists contribute by addressing functional limitations and working to reduce long-term disability. The hands-on involvement of these professionals often allows them to detect early signs of changes in limb temperature, color, or range of motion, as well as shifts in mood, affect, or motivation. These observations should be brought promptly to the attention of the managing physician. In addition, therapy assistants and specialized professionals, such as music, art, play, or shop therapists, may offer valuable insights and therapeutic benefits. Each of these team members plays a role in helping patients adapt, cope, and move toward improved quality of life.
Effective treatment of CPS depends on meaningful education, patient-centered communication, and a commitment to incremental progress. While complete pain elimination may not be possible, an interprofessional team approach can consistently improve functional outcomes and overall well-being.
References
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. The journal of pain. 2009 Sep:10(9):895-926. doi: 10.1016/j.jpain.2009.06.012. Epub [PubMed PMID: 19712899]
Cui CX, Liu HY, Yue N, Du YR, Che LM, Yu JS. Research progress on the mechanism of chronic neuropathic pain. IBRO neuroscience reports. 2023 Jun:14():80-85. doi: 10.1016/j.ibneur.2022.12.007. Epub 2022 Dec 20 [PubMed PMID: 36632243]
Volcheck MM, Graham SM, Fleming KC, Mohabbat AB, Luedtke CA. Central sensitization, chronic pain, and other symptoms: Better understanding, better management. Cleveland Clinic journal of medicine. 2023 Apr 3:90(4):245-254. doi: 10.3949/ccjm.90a.22019. Epub 2023 Apr 3 [PubMed PMID: 37011956]
Level 3 (low-level) evidenceWoolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar:152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.030. Epub 2010 Oct 18 [PubMed PMID: 20961685]
Level 3 (low-level) evidenceMcBeth J, Jones K. Epidemiology of chronic musculoskeletal pain. Best practice & research. Clinical rheumatology. 2007 Jun:21(3):403-25 [PubMed PMID: 17602991]
Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. Clinical and experimental rheumatology. 2017 Sep-Oct:35 Suppl 107(5):79-84 [PubMed PMID: 28967359]
Mutso AA, Petre B, Huang L, Baliki MN, Torbey S, Herrmann KM, Schnitzer TJ, Apkarian AV. Reorganization of hippocampal functional connectivity with transition to chronic back pain. Journal of neurophysiology. 2014 Mar:111(5):1065-76. doi: 10.1152/jn.00611.2013. Epub 2013 Dec 11 [PubMed PMID: 24335219]
Yu R, Gollub RL, Spaeth R, Napadow V, Wasan A, Kong J. Disrupted functional connectivity of the periaqueductal gray in chronic low back pain. NeuroImage. Clinical. 2014:6():100-8. doi: 10.1016/j.nicl.2014.08.019. Epub 2014 Aug 23 [PubMed PMID: 25379421]
Buskila D. Genetics of chronic pain states. Best practice & research. Clinical rheumatology. 2007 Jun:21(3):535-47 [PubMed PMID: 17602998]
Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, Starck LO, Keck PE Jr. Family study of fibromyalgia. Arthritis and rheumatism. 2004 Mar:50(3):944-52 [PubMed PMID: 15022338]
Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. The journal of pain. 2009 Aug:10(8):777-91. doi: 10.1016/j.jpain.2009.06.001. Epub [PubMed PMID: 19638325]
Level 3 (low-level) evidenceClauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997 May-Jun:4(3):134-53 [PubMed PMID: 9500148]
Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. Journal of psychiatric research. 1997 Jan-Feb:31(1):125-31 [PubMed PMID: 9201654]
McLean SA, Clauw DJ. Predicting chronic symptoms after an acute "stressor"--lessons learned from 3 medical conditions. Medical hypotheses. 2004:63(4):653-8 [PubMed PMID: 15325010]
Kato K, Sullivan PF, Evengård B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis and rheumatism. 2006 May:54(5):1682-6 [PubMed PMID: 16646040]
Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis research & therapy. 2006:8(5):218 [PubMed PMID: 16887010]
Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, Olson JM, Iyengar SK. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis and rheumatism. 2013 Apr:65(4):1122-8. doi: 10.1002/art.37842. Epub [PubMed PMID: 23280346]
Dean LE, Arnold L, Crofford L, Bennett R, Goldenberg D, Fitzcharles MA, Paiva ES, Staud R, Clauw D, Sarzi-Puttini P, Jones GT, Ayorinde A, Flüß E, Beasley M, Macfarlane GJ. Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms. Arthritis care & research. 2017 Dec:69(12):1878-1886. doi: 10.1002/acr.23214. Epub 2017 Nov 2 [PubMed PMID: 28182834]
Felson DT, Niu J, Quinn EK, Neogi T, Lewis CL, Lewis CE, Frey Law L, McCulloch C, Nevitt M, LaValley M. Multiple Nonspecific Sites of Joint Pain Outside the Knees Develop in Persons With Knee Pain. Arthritis & rheumatology (Hoboken, N.J.). 2017 Feb:69(2):335-342. doi: 10.1002/art.39848. Epub [PubMed PMID: 27589036]
Neogi T, Frey-Law L, Scholz J, Niu J, Arendt-Nielsen L, Woolf C, Nevitt M, Bradley L, Felson DT, Multicenter Osteoarthritis (MOST) Study. Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state? Annals of the rheumatic diseases. 2015 Apr:74(4):682-8. doi: 10.1136/annrheumdis-2013-204191. Epub 2013 Dec 18 [PubMed PMID: 24351516]
Level 2 (mid-level) evidenceNeogi T, Guermazi A, Roemer F, Nevitt MC, Scholz J, Arendt-Nielsen L, Woolf C, Niu J, Bradley LA, Quinn E, Law LF. Association of Joint Inflammation With Pain Sensitization in Knee Osteoarthritis: The Multicenter Osteoarthritis Study. Arthritis & rheumatology (Hoboken, N.J.). 2016 Mar:68(3):654-61. doi: 10.1002/art.39488. Epub [PubMed PMID: 26554395]
Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology (Oxford, England). 2010 May:49(5):924-8. doi: 10.1093/rheumatology/kep458. Epub 2010 Jan 25 [PubMed PMID: 20100795]
Level 2 (mid-level) evidenceAndersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. The Journal of rheumatology. 2013 Dec:40(12):1977-85. doi: 10.3899/jrheum.130493. Epub 2013 Nov 1 [PubMed PMID: 24187108]
Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbasi-Zender E, Schmitz-Bortz E, Braun J. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatology (Oxford, England). 2018 Sep 1:57(9):1541-1547. doi: 10.1093/rheumatology/kex318. Epub [PubMed PMID: 28968885]
Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford, England). 2018 Aug 1:57(8):1453-1460. doi: 10.1093/rheumatology/key112. Epub [PubMed PMID: 29788461]
Level 1 (high-level) evidenceBello N, Etcheto A, Béal C, Dougados M, Moltó A. Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis. Arthritis research & therapy. 2016 Feb 9:18():42. doi: 10.1186/s13075-016-0943-z. Epub 2016 Feb 9 [PubMed PMID: 26860612]
Magrey MN, Antonelli M, James N, Khan MA. High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study. Arthritis. 2013:2013():762921. doi: 10.1155/2013/762921. Epub 2013 Feb 14 [PubMed PMID: 23476767]
Level 3 (low-level) evidenceTorrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Pérez-Vicente S, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Ibañez-Ruán J, Horcada L, Sánchez-Atrio A, Montilla C, Rodríguez-Gómez M, Díez-Álvarez E, Martinez-Taboada V, Andreu JL, Fernández-Berrizbeitia O, Hernández-Beriain JA, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Marras C, Bonilla G, Pego-Reigosa JM, RELESSER Study Group of the Spanish Society of Rheumatology (SER), Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus. Clinical and experimental rheumatology. 2016 Mar-Apr:34(2 Suppl 96):S40-7 [PubMed PMID: 26575317]
Wolfe F, Petri M, Alarcón GS, Goldman J, Chakravarty EF, Katz RS, Karlson EW. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. The Journal of rheumatology. 2009 Jan:36(1):82-8. doi: 10.3899/jrheum.080212. Epub [PubMed PMID: 19004039]
Nordeman L, Gunnarsson R, Mannerkorpi K. Prevalence and characteristics of widespread pain in female primary health care patients with chronic low back pain. The Clinical journal of pain. 2012 Jan:28(1):65-72. doi: 10.1097/AJP.0b013e318223622c. Epub [PubMed PMID: 21677567]
Level 2 (mid-level) evidenceKlit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. The Lancet. Neurology. 2009 Sep:8(9):857-68. doi: 10.1016/S1474-4422(09)70176-0. Epub [PubMed PMID: 19679277]
Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ (Clinical research ed.). 2014 Feb 5:348():f7656. doi: 10.1136/bmj.f7656. Epub 2014 Feb 5 [PubMed PMID: 24500412]
Misra UK, Kalita J, Kumar B. A study of clinical, magnetic resonance imaging, and somatosensory-evoked potential in central post-stroke pain. The journal of pain. 2008 Dec:9(12):1116-22. doi: 10.1016/j.jpain.2008.06.013. Epub 2008 Oct 10 [PubMed PMID: 18848810]
Stretanski MF. Neuromodulation of neuropathic pain syndrome induced by elapidae (cobra) envenomation. Neuromodulation : journal of the International Neuromodulation Society. 2009 Jan:12(1):44-8. doi: 10.1111/j.1525-1403.2009.00187.x. Epub [PubMed PMID: 22151222]
Staud R, Robinson ME, Price DD. Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. The journal of pain. 2007 Nov:8(11):893-901 [PubMed PMID: 17681887]
Lesuis N, van Vliet J, Boers N, den Broeder N, Cats H, Hulscher ME, Verrips A, den Broeder AA. The value of routine creatine kinase and thyroid stimulating hormone testing in patients with suspected fibromyalgia: a cross-sectional study. Rheumatology (Oxford, England). 2016 Jul:55(7):1273-6. doi: 10.1093/rheumatology/kew046. Epub 2016 Mar 30 [PubMed PMID: 27032423]
Level 2 (mid-level) evidenceNeblett R, Cohen H, Choi Y, Hartzell MM, Williams M, Mayer TG, Gatchel RJ. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. The journal of pain. 2013 May:14(5):438-45. doi: 10.1016/j.jpain.2012.11.012. Epub 2013 Mar 13 [PubMed PMID: 23490634]
Level 2 (mid-level) evidenceTimmerman H, Wolff AP, Bronkhorst EM, Wilder-Smith OHG, Schenkels MJ, van Dasselaar NT, Huygen FJPM, Steegers MAH, Vissers KCP. Avoiding Catch-22: validating the PainDETECT in a in a population of patients with chronic pain. BMC neurology. 2018 Jun 29:18(1):91. doi: 10.1186/s12883-018-1094-4. Epub 2018 Jun 29 [PubMed PMID: 29958535]
Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E. An fMRI-based neurologic signature of physical pain. The New England journal of medicine. 2013 Apr 11:368(15):1388-97. doi: 10.1056/NEJMoa1204471. Epub [PubMed PMID: 23574118]
Jensen KB, Srinivasan P, Spaeth R, Tan Y, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, Williams SC, Choy E, Vitton O, Gracely R, Ingvar M, Kong J. Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain. Arthritis and rheumatism. 2013 Dec:65(12):3293-303. doi: 10.1002/art.38170. Epub [PubMed PMID: 23982850]
Napadow V, Kim J, Clauw DJ, Harris RE. Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia. Arthritis and rheumatism. 2012 Jul:64(7):2398-403. doi: 10.1002/art.34412. Epub [PubMed PMID: 22294427]
López-Solà M, Woo CW, Pujol J, Deus J, Harrison BJ, Monfort J, Wager TD. Towards a neurophysiological signature for fibromyalgia. Pain. 2017 Jan:158(1):34-47. doi: 10.1097/j.pain.0000000000000707. Epub [PubMed PMID: 27583567]
Usui C, Soma T, Hatta K, Aratani S, Fujita H, Nishioka K, Machida Y, Kuroiwa Y, Nakajima T, Nishioka K. A study of brain metabolism in fibromyalgia by positron emission tomography. Progress in neuro-psychopharmacology & biological psychiatry. 2017 Apr 3:75():120-127. doi: 10.1016/j.pnpbp.2017.01.012. Epub 2017 Jan 30 [PubMed PMID: 28153806]
Lee U, Kim M, Lee K, Kaplan CM, Clauw DJ, Kim S, Mashour GA, Harris RE. Functional Brain Network Mechanism of Hypersensitivity in Chronic Pain. Scientific reports. 2018 Jan 10:8(1):243. doi: 10.1038/s41598-017-18657-4. Epub 2018 Jan 10 [PubMed PMID: 29321621]
Brummett CM, Urquhart AG, Hassett AL, Tsodikov A, Hallstrom BR, Wood NI, Williams DA, Clauw DJ. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis & rheumatology (Hoboken, N.J.). 2015 May:67(5):1386-94. doi: 10.1002/art.39051. Epub [PubMed PMID: 25772388]
Level 2 (mid-level) evidenceKnotkova H, Hamani C, Sivanesan E, Le Beuffe MFE, Moon JY, Cohen SP, Huntoon MA. Neuromodulation for chronic pain. Lancet (London, England). 2021 May 29:397(10289):2111-2124. doi: 10.1016/S0140-6736(21)00794-7. Epub [PubMed PMID: 34062145]
Grinberg K, Weissman-Fogel I, Lowenstein L, Abramov L, Granot M. How Does Myofascial Physical Therapy Attenuate Pain in Chronic Pelvic Pain Syndrome? Pain research & management. 2019:2019():6091257. doi: 10.1155/2019/6091257. Epub 2019 Dec 12 [PubMed PMID: 31915499]
Moore NZ, Lempka SF, Machado A. Central neuromodulation for refractory pain. Neurosurgery clinics of North America. 2014 Jan:25(1):77-83. doi: 10.1016/j.nec.2013.08.011. Epub 2013 Oct 10 [PubMed PMID: 24262901]
American College of Rheumatology Pain Management Task Force. Report of the American College of Rheumatology Pain Management Task Force. Arthritis care & research. 2010 May:62(5):590-9. doi: 10.1002/acr.20005. Epub [PubMed PMID: 20461782]
Borenstein DG, Hassett AL, Pisetsky D. Pain management in rheumatology research, training, and practice. Clinical and experimental rheumatology. 2017 Sep-Oct:35 Suppl 107(5):2-7 [PubMed PMID: 28967362]
Wang EJ. Interventional pain procedures and vasovagal reactions: Proceed with vigilance. Interventional pain medicine. 2022 Sep:1(3):100107. doi: 10.1016/j.inpm.2022.100107. Epub 2022 Jun 22 [PubMed PMID: 39238529]
Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of Linezolid With Risk of Serotonin Syndrome in Patients Receiving Antidepressants. JAMA network open. 2022 Dec 1:5(12):e2247426. doi: 10.1001/jamanetworkopen.2022.47426. Epub 2022 Dec 1 [PubMed PMID: 36534400]
Racz R, Soldatos TG, Jackson D, Burkhart K. Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis. Clinical and translational science. 2018 May:11(3):322-329. doi: 10.1111/cts.12543. Epub 2018 Mar 25 [PubMed PMID: 29575568]
Xue H, Thaivalappil A, Cao K. The Potentials of Methylene Blue as an Anti-Aging Drug. Cells. 2021 Dec 1:10(12):. doi: 10.3390/cells10123379. Epub 2021 Dec 1 [PubMed PMID: 34943887]
Salz T, Chimonas S, Jinna S, Brens J, Kriplani A, Salner A, Rabinowits G, Currier B, Daly B, Korenstein D. Pain management for post-treatment survivors of complex cancers: a qualitative study of opioids and cannabis. Pain management. 2024 Feb:14(2):87-99. doi: 10.2217/pmt-2023-0067. Epub 2024 Feb 6 [PubMed PMID: 38318666]
Level 2 (mid-level) evidenceFinan PH, Buenaver LF, Bounds SC, Hussain S, Park RJ, Haque UJ, Campbell CM, Haythornthwaite JA, Edwards RR, Smith MT. Discordance between pain and radiographic severity in knee osteoarthritis: findings from quantitative sensory testing of central sensitization. Arthritis and rheumatism. 2013 Feb:65(2):363-72. doi: 10.1002/art.34646. Epub [PubMed PMID: 22961435]
Lee YC, Lu B, Boire G, Haraoui BP, Hitchon CA, Pope JE, Thorne JC, Keystone EC, Solomon DH, Bykerk VP. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Annals of the rheumatic diseases. 2013 Jun:72(6):949-54. doi: 10.1136/annrheumdis-2012-201506. Epub 2012 Jul 11 [PubMed PMID: 22791744]
Level 2 (mid-level) evidenceChakr RMDS, Brenol C, Ranzolin A, Bernardes A, Dalosto AP, Ferrari G, Scalco S, Olszewski V, Kohem C, Monticielo O, Brenol JCT, Xavier RM. Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia. Revista brasileira de reumatologia. 2017 Sep-Oct:57(5):403-411. doi: 10.1016/j.rbre.2017.01.004. Epub 2017 Feb 10 [PubMed PMID: 29037312]
Koop SM, ten Klooster PM, Vonkeman HE, Steunebrink LM, van de Laar MA. Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis. Arthritis research & therapy. 2015 Sep 3:17(1):237. doi: 10.1186/s13075-015-0761-8. Epub 2015 Sep 3 [PubMed PMID: 26335941]
Level 2 (mid-level) evidenceMeeus M, Vervisch S, De Clerck LS, Moorkens G, Hans G, Nijs J. Central sensitization in patients with rheumatoid arthritis: a systematic literature review. Seminars in arthritis and rheumatism. 2012 Feb:41(4):556-67. doi: 10.1016/j.semarthrit.2011.08.001. Epub 2011 Oct 28 [PubMed PMID: 22035625]
Level 1 (high-level) evidenceEdwards RR, Dolman AJ, Martel MO, Finan PH, Lazaridou A, Cornelius M, Wasan AD. Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis. BMC musculoskeletal disorders. 2016 Jul 13:17():284. doi: 10.1186/s12891-016-1124-6. Epub 2016 Jul 13 [PubMed PMID: 27412526]
Hirakawa K, Nakayama A, Arimitsu T, Kon K, Ueki H, Hori K, Ishimoto Y, Ogawa A, Higuchi R, Hosoya Y, Nanasato M, Isobe M. Feasibility and safety of upper limb extremity ergometer exercise in the cardiac intensive care unit in critically ill patients with cardiac disease: a prospective observational study. Frontiers in physiology. 2025:16():1448647. doi: 10.3389/fphys.2025.1448647. Epub 2025 Mar 28 [PubMed PMID: 40224148]
Level 2 (mid-level) evidenceSzczotkowski D, Meyer-Moock S, Kohlmann T, Deppe K, Gärtner A, Hoffmann G, Isenberg T, Lindena G, Marschall U, Martin C, Metz-Oster B, Milch L, Möller A, Nagel B, Petzke F, Preissler A, Pritzke-Michael J, Schouten L, Schwenk K, Schumacher C, Waidner A, Kaiser U. Evaluating an early Interdisciplinary Multimodal Assessment for Patients at Risk of Developing Chronic Pain: Results of a Multicentre RCT in Germany. Pain and therapy. 2025 Apr 15:():. doi: 10.1007/s40122-025-00729-3. Epub 2025 Apr 15 [PubMed PMID: 40232611]